Edition:
United Kingdom

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

13.03USD
8:59pm GMT
Change (% chg)

$0.18 (+1.40%)
Prev Close
$12.85
Open
$12.90
Day's High
$13.10
Day's Low
$12.79
Volume
34,596
Avg. Vol
8,134
52-wk High
$13.30
52-wk Low
$2.77

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $131.52
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-GTX reports qtrly ‍loss per share $0.53​

* GTX provides corporate update and reports third quarter 2017 financial results

14 Nov 2017

BRIEF-GTX Inc files for offering of up to 8.8 million shares of common stock

* GTX Inc files for offering of up to 8.8 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2zotwFH) Further company coverage:

20 Oct 2017

BRIEF-Amzak Health Investors Llc reports 6.15 pct passive stake in GTX as of Sept 29

* Amzak Health Investors Llc reports 6.15 percent passive stake in GTX Inc as of September 29 - SEC Filing‍​ Source text: (http://bit.ly/2zdLcEN) Further company coverage:

10 Oct 2017

BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29

* Aisling Capital IV LP reports 6.2 percent passive stake in GTX Inc as of Sept 29 - SEC Filing Source text: (http://bit.ly/2xW9yVO) Further company coverage:

05 Oct 2017

BRIEF-Gtx announces closing of $48.5 million private placement

* Gtx announces closing of $48.5 million private placement Source text for Eikon: Further company coverage:

29 Sep 2017

BRIEF-GTx announces $48.5 million private placement

* GTx - ‍entered into agreement for sale of its common stock & warrants to purchase common stock in private placement with gross proceeds of $48.5 million

26 Sep 2017

BRIEF-GTx announces positive results from enobosarm Phase 2 proof-of-concept clinical trial

* GTx announces positive results from enobosarm phase 2 proof-of-concept clinical trial in women with stress urinary incontinence

13 Sep 2017

BRIEF-GTx Q2 loss per share $0.40

* Gtx provides corporate update and reports second quarter 2017 financial results

14 Aug 2017

Earnings vs. Estimates